

LASA SUPERGENERICS LIMITED

Corporate Office: Office No. 705, Minerva Estate, Asha Nagar A Wing, O2 Commercial Tower, Mulund (West), Mumbai-400 080

Email: info@lasalabs.com • Website: www.lasalabs.com

Ref. No.: LASA/SE/21-22/27

Monday, August 23 2021

То,	То,
Corporate Services Department	Corporate Services Department
BSE Limited	National Stock Exchange of India Limited
Phiroze Jeejeebhoy Towers,	"Exchange Plaza", Plot No. C/1,
Dalal Street,	G Block Bandra-Kurla Complex,
Mumbai - 400 001.	Bandra (E), Mumbai - 400 051.
BSE CODE -540702	NSE CODE: LASA

Sub. : Media Release

Dear Sir,

Attached is a copy of Press Release tilted "LASA SUPERGENERICS RESUMES OPERATIONS IN ALL UNITS SITUATED IN MAHAD AND CHIPLUN." Issued by the company.

You are requested to note the above on your records.

THANKING YOU
YOURS SINCERELY
FOR LASA SUPERGENERICS LIMITED

NIDHI KULSHRESHTHA

COMPANY SECRETARY AND COMPLIANCE OFFICER



Lasa Supergenerics Limited

CIN: L24233MH2016PLC274202

Media Release

LASA SUPERGENERICS RESUMES OPERATIONS IN ALL UNITS SITUATED IN MAHAD AND CHIPLUN

Mumbai, 23th August 2021: Lasa Supergenerics Limited, a vertically integrated group spanning the entire animal and human healthcare value chain has announced a calibrated restart of manufacturing operations in plants located at Mahad, Dist Raigad. The Company managed to resume operations in units situated in Chiplun within a week of floods.

With this companies all units stands operational.

Commenting on the recent development, Dr. Omkar Herlekar, Chairman & Managing Director, Lasa Supergenerics Limited said:

It is heartening to comment on restart of activities we are fortunate enough to come back soon with the efforts of our dedicated team, we are also targeting to meet the time gap of production in a quarter and we are confident enough to surpass all our previous records with respect to production.

We are cautiously optimistic and staying agile to cater to an evolving demand, we are committed to grow and I assure that we will not leave any stone unturned to achieve our goals.

At this juncture once again I would like to thank our management team, our suppliers who came forward to support in this testing times so that we can restart our operations at the earliest. I sincerely thank the entire team of 'LASA' for their untiring efforts, hard work, sincerity and high dedication. Also, I would like to thank our valued Shareholders, whose support and faith in our Company has given us the determination and ambition to go from strength to strength."

About Lasa Supergenerics Limited (www.lasalabs.com/; BSE: 540702; NSE: LASA)

Incorporated in 2011, Lasa Supergenerics Limited is a globally well trusted brand with high quality products, accepted by large companies across the globe. Our Company is the pioneer and amongst the leading players in the manufacturing of Veterinary APIs, with a well-established brand known for its high-quality products amongst various customers. The Company has its unit with state of art manufacturing facilities located atMahad & Chiplun, Maharashtra with a total installed capacity of 4,300 MT. The Company has over 25% of APIs exported to counties like Australia, Bangladesh, Middle East, China, Turkey, Egypt, Jordan, Korea, Pakistan etc.



Lasa Supergenerics Limited

CIN: L24233MH2016PLC274202

For more details please visit: www.lasalabs.com
For any Investor Relations query, please contact:

Mr. Hitesh Wadhwani

Lasa Supergenerics Limited

Email: hitesh@lasalabs.com

Note: Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments, and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Further, past performance is not necessarily indicative of future results. Given these risks, uncertainties and other risk factors, viewers are cautioned not to place undue reliance on these forward-looking statements. Lasa Supergenerics Ltd. will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.